Cartalax 20mg
$ 80.00 CAD
Cartalax is a cartilage bioregulator built from the tripeptide Ala-Glu-Asp. It targets cartilage, connective tissue and the joint capsule, making it the go-to bioregulator for anyone whose joints are the limiting factor rather than their muscles. Researchers pair it with BPC-157 and TB-500 for a full connective tissue protocol.
Cartalax 20mg: The Cartilage and Joint Bioregulator
Every serious lifter eventually hits the same wall. The muscle can handle the load but the joints cannot. Knees, shoulders, elbows and hips take the beating that heavy training delivers, and cartilage is the slowest tissue in the body to repair because it has almost no direct blood supply.
Cartalax is a short peptide bioregulator derived from cartilage tissue, built from the tripeptide sequence Ala-Glu-Asp. It is part of the Khavinson bioregulator family and is the cartilage-specific member of that series.
What the Research Covers
- Cartilage tissue. Research has focused on chondrocyte function and cartilage matrix synthesis.
- Joint function. Studies have looked at osteoarthritis models and age-related joint degradation.
- Connective tissue. Broader musculoskeletal research covers tendon and ligament support alongside cartilage.
- Inflammatory markers. Some research has measured inflammatory response in joint tissue.
Why Athletes and Lifters Use It
Cartalax fills the gap that healing peptides alone do not cover. BPC-157 works strongly at the injection site and TB-500 travels systemically, but neither is cartilage-specific the way a bioregulator is. Researchers running joint protocols commonly stack all three so the local, systemic and tissue-specific angles are all covered.
If your training is limited by joint pain rather than strength or conditioning, this is the compound in the bioregulator line most relevant to you.
Specs
- Sequence: Ala-Glu-Asp (tripeptide)
- Vial size: 20mg lyophilized powder
- Class: Khavinson short peptide bioregulator
- Target tissue: Cartilage, connective tissue
- Storage: Refrigerate. Stable long-term unmixed.
Reconstitution and Storage
Ships as a sterile lyophilized powder. Reconstitute with bacteriostatic water. Once mixed, store refrigerated and use within 30 days. Keep the vial out of direct light and avoid repeated warming and cooling cycles.
For laboratory and research use only. Not for human consumption. Not approved by Health Canada for therapeutic use.
| Country | Canada, USA |
|---|---|
| Dosage | 20mg |
Cartalax: Dosage Protocol
- Short course
- Often 10mg a day, 10 to 20 days
- Step-up
- 2mg rising to 5mg over 12 weeks
- How often
- Once a day
- Route
- Subcutaneous
- Time off
- 10 to 30 days, or repeat every 3 to 6 months
- Vials
- 5 for 10 days at 10mg
1. Mix it and draw it
Put 2mL of bac water into the 20mg vial. That makes 10mg per mL. On a 100-unit insulin pin, 10 units = 1mg. Units measure volume, not milligrams, so this only holds if you used 2mL of water.
| Protocol | Dose | Pull to | Shots per vial |
|---|---|---|---|
| Step-up, weeks 1-2 | 2mg | 20 units | 10 |
| Step-up, weeks 3-4 | 3mg | 30 units | 6 |
| Step-up, weeks 5-8 | 4mg | 40 units | 5 |
| Step-up, weeks 9-12 | 5mg | 50 units | 4 |
| Short course | 10mg | 100 units | 2 |
10mg drawn up.
- Swab the stopper. Run the water down the side of the glass, slowly.
- Swirl, do not shake. It should go clear.
- Pinch skin on the belly or thigh, inject, move to a new spot next time.
2. The schedule
Typical run shown below: 10 days. Time off after: 3 to 6 months.
One box = one week of the year. Red = on. 10 days per run.
3. Why this dose
Two ways to run it. The classic Russian short course is 10 to 20 days, often at 10mg a day, with lower doses also used subQ. At 10mg you pull half a vial per shot. The other is a 12-week step-up: 2mg a day for two weeks, 3mg for two, 4mg for four, 5mg for four. That one adds up to about 320mg, so 16 vials. Neither was ever tested in a trial.
4. The evidence, ranked
Level 1 of 4. Cell and tissue culture only.
| Study | What they did and found |
|---|---|
| Lin'kova 2016, Bull Exp Biol MedPMID 27259496 | Fibroblasts aged in culture. AED cut MMP-9, raised Ki-67 and CD98hc, and reduced caspase-3 cell death. |
| Chalisova 2015, Bull Exp Biol MedPMID 26033601 | Cartalax and related peptides tested on kidney tissue cultures from young and old animals. |
| Khavinson 2021, MoleculesPMID 34834147 | The group's own review of how these short peptides act on genes. Good overview, written by the people who make them. |
5. What you are injecting
3 amino acids in a chain. Formula C12H19N3O8, molecular weight 333.3 g/mol.
Cartalax is the three amino acid peptide AED. In ageing fibroblasts, the cells that build connective tissue, it turned down MMP-9 (an enzyme that chews through the tissue matrix) and turned up markers of cell turnover. Less breakdown, more renewal. That is why it gets used alongside BPC-157 and TB-500 for joints.
6. The gaps
Despite the name, the published work is on skin fibroblasts and kidney tissue, not on a damaged knee. No one has shown an injected course rebuilds cartilage in a person. Run it as an add-on, not as the fix.
7. Keeping it good
| Unmixed | Fridge, out of the light. Freezer if you are holding it for months. |
|---|---|
| Mixed | Fridge. Use inside 30 days. |
| Bin it if | It goes cloudy, has floaters, or sat warm for a day. |
Information on this tab comes from published studies and reported use. For laboratory and research use only. Not for human consumption. Not approved by Health Canada for therapeutic use.
Be the first to review “Cartalax 20mg”
You must be logged in to post a review.
Related products
Peptides
Peptides
Peptides
Peptides
Peptides
Peptides
Reviews
There are no reviews yet.